Targeted and MMP-2/9 responsive peptides for the treatment of rheumatoid arthritis

This study establishes adjuvant-induced arthritis (AIA) mouse models and explores the anti-inflammatory efficacy of QAW in AIA mice. To enhance the targeting, responsiveness, and efficacy of QAW to inflammation, QAW (Q) is modified with a cell penetrating peptide (T), a matrix metalloproteases-2/9 (MMP-2/9) digestive peptide (M), and an inflammation targeting peptide-RGD (R). The designed RMTQ demonstrates enhanced delivery to cytoplasm, higher reduction of pro-inflammatory factors, and better efficacy than QAW. The anti-inflammatory efficacy of RMTQ is similar to that of DEX in this study whereas RMTQ treatment shows a higher safety than that of DEX. In sum, this study demonstrates that RMTQ can be a potential therapeutic for inflammatory arthritis.Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

CONCLUSIONS: Seasonal variations in infectious agents, sun exposure, and food ingestion during gestation or early infancy seem to explain the association between birth month/season and development of rheumatic diseases. PMID: 31498065 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
CONCLUSION: The prognosis of lupus does not seem to be aggravated by PG and the treatments of a SLE flare are usually enough for treating associated PG. PMID: 31495525 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Conclusions: Rituximab is both safe and effective for the treatment of acquired angioedema with C1-inhibitor deficiency, ANCA-associated vasculitis, autoimmune hemolytic anemia, Behçet’s disease, bullous pemphigoid, Castleman’s disease, cryoglobulinemia, Goodpasture’s disease, IgG4-related disease, immune thrombocytopenia, juvenile idiopathic arthritis, membraneous nephropathy, relapsing-remitting multiple sclerosis, myasthenia gravis, nephrotic syndrome, neuromyelitis optica, pemphigus, rheumatoid arthritis, spondyloarthropathy, and systemic sclerosis. Conversely, rituximab failed to show an effec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Atopic dermatitis (AD) is associated with a wide range of comorbidities, particularly allergies, but its association with nonatopic autoimmune disease is less well defined. Recent genome-wide association studies have reported shared genetic loci between AD and autoimmune diseases. In the UK, most patients with these conditions are managed in primary care, meaning general practice (GP) databases provide a rich data source for studying AD. A retrospective cohort study was undertaken to examine the association between AD and the following autoimmune diseases (rheumatoid arthritis [RA], ulcerative colitis [UC], Crohn ’s ...
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
Pyoderma gangrenosum (PG) is a sterile, idiopathic, ulcerative, neutrophilic dermatosis that can be associated with trauma or systemic diseases. The lesion typically begins as a pustule that later progresses to an ulcer or deep erosion with violaceous undermined borders. Diagnosis of PG is based on histopathology as well as exclusion of other diagnoses. Approximately 50% of PG cases are associated with systemic diseases, which include inflammatory bowel disease (IBD), rheumatoid arthritis, and hematologic malignancies.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
The objective of this study is to describe the epidemiological trend of PG patients in a university-based wound care outpatient center, focusing on demographics, comorbidities, and treatments.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Humira is the best-selling medicine in the world and a gold mine for drug maker AbbVie, bringing in $4.87 billion in revenue globally in the second quarter. The drug, which treats rheumatoid arthritis and Crohn's disease, costs upwards of $60,000 a year. So it may come as no surprise that Humira is on the list of the 25 most costly drugs for Oregon health insurers in 2018. The combined list is based on the rankings submitted by nine insurance comp anies and takes into account total annual spending,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
AbstractThe immune system when acts against selfmolecules results in an imbalance in immunologic tolerance leading to the development of several autoimmune diseases (ADs) such as rheumatoid arthritis, asthma, ulcerative colitis, type 1 diabetes, and multiple sclerosis. Improved recognition of the mechanisms of ADs has led to the advancement of the management of these diseases. The principal mediators of ADs are inflammatory molecules. The herbal medicines due to their antioxidant and antiinflammatory properties have an important role in the management of ADs. Crocin is the principal chemical component extracted from saffro...
Source: BioFactors - Category: Biochemistry Authors: Tags: REVIEW ARTICLE Source Type: research
Date: August 26, 2019 Issue #:  1579Summary:  The FDA has required updates to the labeling of the Janus kinase (JAK) inhibitor tofacitinib(Xeljanz, Xeljanz XR) based on interim results of a postmarketing safety trial that showed an increased risk of pulmonary thromboembolism and death with a dosage of 10 mg twice daily.1 Tofacitinib is approved for treatment of rheumatoid arthritis (RA),2 psoriatic arthritis, and ulcerative colitis.In the postmarketing trial, RA patients ≥50 years old taking methotrexate who had at least one cardiovascular risk factor were randomized to receive add-on treatm...
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research
ConclusionWe describe a novel adjustment method for interdisease treatment differences using infliximab treatment patterns to bridge differences between IBD and RA. After adjustment, adherence was higher with infusions than oral medications, which may affect outcomes. Indirect comparisons between vedolizumab and tofacitinib are not generalizable and should be confirmed in tofacitinib-treated IBD patients.FundingTakeda Pharmaceuticals U.S.A., Inc.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Drugs & Pharmacology | Inflammatory Bowel Disease | Rheumatoid Arthritis | Rheumatology | Study